Macrogenics reported $21.47M in Cash and Equivalent for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Amgen AMGN:US $ 5203M 1325M
AstraZeneca AZN:LN 395649.11M 43092.62M
Biogen BIIB:US $ 2646.6M 897.3M
Bristol Myers Squibb BMY:US $ 10750M 1619M
Cerulean Pharma CERU:US $ 39.32M 12.36M
Daiichi Sankyo 4568:JP Y 658064M 4413M
Eli Lilly And LLY:US $ 2622.9M 163.7M
Epizyme EPZM:US $ 71.07M 6.36M
Genmab GEN:DC DK 9816M 745M
Geron GERN:US $ 76.06M 44.73M
Gilead Sciences GILD:US $ 7000M 2704M
Immunogen IMGN:US $ 373.87M 63.79M
Karyopharm Therapeutics KPTI:US $ 82.25M 71.01M
Macrogenics MGNX:US $ 21.47M 25.86M
Mirati Therapeutics MRTX:US $ 245.51M 47.91M
Puma Biotechnology PBYI:US $ 52.76M 11.16M
Regeneron Pharmaceuticals REGN:US $ 3395.1M 49.4M
Seattle Genetics SGEN:US $ 364.87M 103.88M
Xencor XNCR:US $ 49.41M 28.86M